AIIMS Delhi Starts Registration for Conducting Human Trials of COVID-19 Vaccine COVAXIN

New Delhi: The All India Institute of Medical Science (AIIMS), Delhi has started the registration process for conducting the human trials of COVAXIN today.

The AIIMS Ethics Committee has given its approval for conducting the human clinical trial of the indigenously developed Covid-19 vaccine candidate COVAXIN.

AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting phase I and II human trials of COVAXIN, which has been jointly developed by the Indian Council of Medical Research (ICMR) and Bharat Biotech International Limited (BBIL).